GLP-1 receptor agonist therapy before bariatric surgery: Effects on weight loss and body composition in clinical practice.

Obesity research & clinical practice

Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial.

JAMA network open

Targeting mTOR with vistusertib attenuates metabolic steatohepatitis and prevents HCC development.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]

Association of Glucagon-like Peptide-1 Receptor Agonist Use with Stroke and Mortality Outcomes in Asymptomatic Intracranial Atherosclerotic Disease: Propensity Score-Matched Real-World Analysis.

Neurology international

Semaglutide targets the Isg15-FUNDC1 axis: suppressing IFN-β overactivation and attenuating blood-brain barrier injury in diabetic intracerebral hemorrhage.

Journal of neuroinflammation

Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us.

Nature communications

Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial.

Annals of internal medicine

To Reenvision and Redefine: Considering the Role of Lifestyle Interventions in the New Era of Second-Generation Obesity Management Medications.

Current atherosclerosis reports

Everyone says peptides cause cancer. I pulled the studies. Here's what they actually show. 06:25 BPC-157 08:40 DSIP 09:54 Epitalon 12:15 GHK-Cu 14:45 KPV 16:03 LL-37 18:41 MOTS-c 20:00 Retatrutide 21:19 Semaglutide 22:24 SS-31 24:13 Thymosin Alpha-1 25:47 Tirzepatide https://t.co/2RBkMubEQP

RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…

RT @afshineemrani: 2/5 The study matched patients on GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, and others — against…

What 2026 research-chem buyers actually order — top 10 by share of all in-scope COAs in our corpus over the last 60 days: Retatrutide — 10.4% Tirzepatide — 8.5% BPC-157 — 7.8% GHK-Cu — 4.8% Tesamorelin — 4.4% MOTS-C — 4.1% Ipamorelin — 3.8% NAD+ — 3.2% Semaglutide — 3.1% TB-500

Why Retatrutide is Better Than Other GLP-1s: 1. Triple Action Power • Retatrutide activates GLP-1, GIP, and glucagon receptors — most others only target GLP-1 (like Semaglutide) or GLP-1 + GIP (like Tirzepatide). https://t.co/d5qjmF2BX1 https://t.co/wOBoPEcVsW

@LisaD138845 @elonmusk @tunguz **GLPs (GLP-1 receptor agonists) like Ozempic/Wegovy (semaglutide) and Zepbound/Mounjaro (tirzepatide) are synthetic peptide drugs.** **Active ingredient:** - Ozempic/Wegovy: semaglutide (lab-made GLP-1 analog) - Zepbound/Mounjaro: tirzepatide (dual GLP-1/GIP agonist)

@ThePepGuy verve 102 results are interesting peptide therapy also shows promise for lipid profiles bpc 157 and tb 500 have been studied for their effects on inflammation and cardiovascular health worth looking into the molecular mechanisms behind them.

retatrutide Phase 3 data just dropped. 28.3% average weight loss at 80 weeks (12mg dose). for context: tirzepatide peaked at 22.5% in SURMOUNT-1. semaglutide hit 16.9% in STEP 1. triple agonist (GLP-1 + GIP + glucagon) vs dual for tirzepatide, single for semaglutide.